Pulin S. Kothari, Peter T. Scardino, Makoto Ohori, Michael W. Kattan, Thomas M. Wheeler
4 min
While the prognostic significance of pelvic lymph node metastasis in prostate cancer is well-established, the role of lymph nodes located directly within the periprostatic and periseminal vesicle (PP/PSV) fat has remained largely unexamined. This study aimed to determine the incidence, anatomical distribution, and clinical significance of these nodes in patients undergoing radical prostatectomy.
The researchers reviewed whole-mount pathology slides from 832 patients who underwent radical retropubic prostatectomy between 1983 and 1998. They specifically searched for lymph nodes within the adipose tissue surrounding the prostate and seminal vesicles. Any identified nodes were confirmed microscopically and assessed for metastatic disease. The study then compared clinical outcomes, such as recurrence rates and pathologic staging, between patients with and without metastatic involvement of these specific nodes.
PP/PSV lymph nodes were identified in 4.4% of the study population. Metastatic prostate cancer was found in the PP/PSV lymph nodes of five patients (0.6%). Notably, in three of these five cases, the metastases were isolated to the PP/PSV nodes, meaning the pelvic lymph nodes were negative. These patients exhibited significantly higher tumor volumes and Gleason scores compared to those without PP/PSV node involvement. Furthermore, 80% of patients with positive PP/PSV nodes experienced cancer recurrence. The authors suggest that because these nodes can be a site of isolated metastasis, they should be formally recognized in the AJCC Staging Manual as "N1" status when positive.
This research highlights a potential "blind spot" in standard prostate cancer staging. Because these nodes are often too small to be detected without meticulous whole-mount sectioning, they may be overlooked during routine pathological examination. The findings suggest that the periseminal vesicle fat is a critical area for sampling, as it is a common site for these nodes and their associated metastases. Recognizing these nodes as a site of disease spread could improve the accuracy of prognostic assessments for patients with localized prostate cancer.
Sam: Then the evidence that carries weight is the skip pattern. Three of five with negative pelvic nodes is the part that can't be explained by seminal vesicle invasion alone.
Alex: Right, though even that is five patients. It does suggest staging has a resolution problem. If these nodes could be mapped preoperatively, that might change surgical planning or the decision to use adjuvant therapy. The paper frames that as a possibility, not something it tested.
Sam: So pelvic node status looks like an insufficient proxy for true nodal burden. A clear pelvic chain doesn't rule out disease in the periprostatic fat.
Alex: And the authors go a step further. They argue these nodes should be formally included in the American Joint Committee on Cancer staging manual and classified as N1, to reflect their clinical weight.
Sam: Which is a strong recommendation to rest on five events. But it does expose how much our definition of localized disease depends on how closely we look.
Alex: If you want the figures and the method choices we skipped, you can generate a deep dive of this paper. The paper has the rest either way.
Sam: Thanks for listening.